A Novel Drug Candidate that Selectively Targets the Critical Androgen Receptor-ELK1 Growth Axis in Advanced and Drug-Resistant Prostate Cancer
Claire L. Soave, Lisa Polin, Charles E. Ducker, Vy Ong, Seongho Kim, Luke Pardy, Jing Li, Xun Bao, Yanfang Huang, Peter E. Shaw, Rahul S. Khupse, Manohar Ratnam
This paper develops a new compound KCI838 that selectively inhibits the AR-ELK1 axis in prostate cancer, showing potent anti-tumor activity in resistant models.
bioRxiv · May 29, 2026 · PreprintCancer Biology